WHI and breast cancer risk: The same old story

摘要

WHI investigators keep hammering the issue of hormone therapy (HT) and related increased risk of breast cancer. Their 'money' is actually on what they call the estrogen + progestin (E + P) users, since they cannot claim a real risk in the estrogen-alone users. So now they bring new data from the WHI observational study1. Here is the Abstract:In the WHI randomized trial, estrogen plus progestin increased both breast cancer incidence and mortality. In contrast, most observational studies associate estrogen plus progestin with favorable prognosis for breast cancers. To address differences, a cohort of WHI observational study participants with characteristics similar to the WHI clinical trial was studied. We identified 41 449 postmerro-pausal women with no prior hysterectomy and mammogram-negative within 2 years who were either not hormone users (n = 25 328) or estrogen and progestin users (? = 16 121).